Pretreatment neutrophil-to-lymphocyte ratio and Mean Platelet Volume in castration-resistant prostate cancer patients treated with first-line docetaxel

Background:Patients who have evidence of disease progression (eg, increase in serum prostate-specific antigen PSA, new metastases, progression of existing metastases) while being managed with androgen deprivation therapy (ADT) are considered to have castration-resistant disease. Docetaxel (75 mg/m2) given every three weeks in combination with daily prednisone (5 mg twice a day) significantly prolonged overall survival compared with mitoxantrone plus prednisone in the TAX 327 phase III trial 3. Based upon those results, docetaxel plus prednisone has become the standard initial regimen when chemotherapy is indicated for CRPC Methods: Inflammation-based markers, such as the Neutrophile/Lymphocyte Ratio (NLR), are widely available and inexpensive measurements that are easy to integrate into pretreatment evaluation. Mean platelet volume (MPV) is a marker of activated platelets is associated some types of cancer including ovarian, gastric cancer. We retrospectively evaluated the predictive impact of neutrophil-lymphocyte ratio (NLR) and MPV as a marker for in men with progressive metastatic castration resistant prostate cancer (mCRPC) following docetaxel.Results: A significant correlation was not observed between NLR and PSA response. A significant correlation was not also observed between MPV and PSA response.There no correlation was found between MPV and NLR with total PSA level and response (p:0.355, p:0.673 respectively)Conclusion: . In our study; We didn’t show any correlation between MWP level, NLR ratio and response to Docetaxel therapy A significant correlation was not also observed between NLR , MPV and PSA response.

become the standard initial regimen when chemotherapy is indicated for CRPC Methods: Inflammation-based markers, such as the Neutrophile/Lymphocyte Ratio (NLR), are widely available and inexpensive measurements that are easy to integrate into pretreatment evaluation. Mean platelet volume (MPV) is a marker of activated platelets is associated some types of cancer including ovarian, gastric cancer. We retrospectively evaluated the predictive impact of neutrophillymphocyte ratio (NLR) and MPV as a marker for in men with progressive metastatic castration resistant prostate cancer (mCRPC) following docetaxel.Results: A significant correlation was not observed between NLR and PSA response. A significant correlation was not also observed between MPV and PSA response.There no correlation was found between MPV and NLR with total PSA level and response (p:0.355, p:0.673 respectively)Conclusion: . In our study; We didn't show any correlation between MWP level, NLR ratio and response to Docetaxel therapy A significant correlation was not also observed between NLR , MPV and PSA response.
The disease progression after androgen deprivation therapy (ADT) by surgical or medical orchiectomy is defined as Castration-resistant prostate cancer (CRPC).
There are several strategies including cabazitaxel, abiraterone, enzalutamide and sipuleucel-T have been approved for therapy of these men and several other drugs including novel androgen-modulating approaches [1,2]. Taxanes are the only cytotoxic chemotherapy agents that have significantly prolonged overall survival in clinical trials in men with CRPC. Docetaxel chemotherapy is one of the choices of the therapy. Docetaxel (75 mg/m 2 ) given every three weeks in combination with daily prednisone (5 mg twice a day) significantly prolonged overall survival compared with mitoxantrone plus prednisone in the TAX 327 phase III trial [3].
Based upon these results, docetaxel plus prednisone has become the standard initial regimen when chemotherapy is indicated for CRPC. [3] Serial measurement of serum prostate-specific antigen (PSA) during hormonal therapy is the primary approach for monitoring response to systemic hormonal treatment for men with the rising PSA or disseminated metastases. The frequency of monitoring is influenced by the likelihood of disease progression. [4] The testosterone suppression should be checked when PSA level rises.
Many studies showed the importance of activated platelets in cancer progression and metastasis. [5,6] There are several cancer types like gastric cancer, ovarian cancer, lung cancer, colon cancer and breast cancer in these types of cancers. [7][8][9][10][11] The main aim of our retrospective study was to assess the prognostic value, in terms of response to the therapy in the correlation with NLR and MPV, in patients treated with first-line docetaxel for CRPC.

Methods 4
This retrospective study examined the records of 78 patients the records of 78 patients with a new diagnosis of metastatic castrate resistance prostate adenocarcinoma who received three weekly docetaxel with 5 mg prednisone twice daily. Patient demographics have been summarised in Supplementary Table 1. For the men who develop CRPC as described as , serum levels of testesterone below 50 ng/ml under ADT treatment. Castration resistance was described as biochemical and radiologic progression after androgen deprivation therapy. Catrate levels of testesterone below 50 ng/ml was maintened by contuining LHRH agonist while Docetaxel therapy is applied. All of the patients'treatment responses were detected by bone scintigraphy, torachal and abdominal tomography with total PSA and testesteron level. For radiographic evaluation (i.e., bone scan, pelvic MRI or CT), patients were examined at the start and after 3 or 6 cycles of chemotherapy.Disease progression was defined as an increase of PSAlevel ≥25% relative to the pretreatment PSA baseline with radiologic assesment.

And (or) radiological progression according to the recommendations of Prostate
Cancer Work Group-2 (PCWG-2). For follow-up, PSA and ALP levels were examined once a month and radiographic evaluation were performed every 3months.
Patients'hemogram and biochemical measurements with liver and renal function tests every cycle.
NLR was calculated by dividing absolute neutrophil count by absolute lymphocyte count measured in peripheral blood. The patients were in good performance status (KPS ≥ 70). MPV levels and NLR were divided due to response type.
OS was defined as the time from the start of chemotherapy from the start of the docetaxel treatment to death or the date of last follow-up. 6 Two large randomized phase III clinical trials (TAX 327 and SWOG 99-16) showed a significant survival benefit of docetaxel-based chemotherapy in patients with CRPC, and established its status as the first-line treatment regimen [13,14].Based upon those results of TAX 327 docetaxel plus prednisone has become the standard initial regimen when chemotherapy is indicated for CRPC Serial measurement of serum prostate-specific antigen (PSA) during hormonal therapy is the primary approach for monitoring response to systemic hormonal treatment for mean with a rising PSA or disseminated metastases. The frequency of monitoring is influenced by the likelihood of disease progression. Total PSA is good predictor for measuring treatment response. [15] More than 60 studies showed the prognostic importance of NLR . Prostate cancer is one of these cancers [16][17][18][19] Several prognostic factors were defined fort he men who treated with docetaxel. [20][21][22] The mechanisms underlying the association of MPV is currently unclear. There are many studies which showed the stimulator of cell proliferation/transformation in prostate cancer for the platelet-derived growth factor (PDGF) proteins. [23] PDGF alpha-receptor activation is associated with bone metastases in CRPC . In prostate cancer mice targeting PDGF alpha-receptor effectively counteracts skeletal metastases. [24] These data are also in agreement with MPV is an early marker of activated platelets. Indeed, some drugs, infections, many concurrent conditions can effect neutrophil and lymphocyte counts and MPV levels. Not only these parameters but the combination with other parameters can be useful for evaluation of therapeutic response.

Conclusions
We have investigated the predictive impact of the NLR and MPV for detecting Docetaxel response in men receiving first-line chemotherapy with docetaxel for mCRPC.We show that there are no correlation between pretreatment levels of NLR and MPV with Docetaxel response .Men with an elevated pretreatment NLR of >3.0 were found to be at higher risk of death after adjusting for other prognostic variables due to some studies But these parameters are not predictive for docetaxel response. context of additional therapies for advanced prostate cancer. There are no study about MPV importance for docetaxel response. In our study; We didn't show any correlation between MWP level, NLR ratio and response to Docetaxel therapy A significant correlation was not also observed between NLR , MPV and PSA response.  informed consent to review their medical records was not obtained it was waived by the ethics committee due to the study style as retrospective series. Some of the patients were died when included to the study and these patients were analysed retrospectively.Patients datas confidentiality hidden by study team and the patients names were hidden during the analysis and compliance with the Declaration of Helsinki.

Consent for publication
The results presented in this paper have not been published previously in whole or part.

Competing interests
The authors declare that they have no competing interests.  Median OS 39 months (%95 CI 31-52 months)